Search results
People also ask
Which drug companies make the most money in 2021?
What are the top 10 pharma companies by 2021?
How much money will cancer drugs make in 2021?
Which pharma companies make the most money?
What are the most profitable pharmaceutical companies in the world?
Was 2021 a good year for a pharmaceutical company?
The six largest drugmakers by 2021 revenue—J&J, Pfizer, Roche, AbbVie, Novartis and Merck & Co.—all made the top profit list but in quite a different order.
- The top 20 pharma companies by 2021 revenue
Of the world’s top 20 pharmas ranked by 2021 revenues, 12...
- The top 20 drugs by 2021 sales - Fierce Pharma
With Pfizer and BioNTech’s COVID-19 vaccine Comirnaty...
- The top 20 pharma companies by 2021 revenue
Jun 13, 2023 · According to recent financial statistics, the top pharmaceutical companies in the world include Johnson & Johnson, Pfizer, and Roche, each generating over $50 billion in revenue annually. These...
Of the world’s top 20 pharmas ranked by 2021 revenues, 12 had at least 10% growth, including five that saw their sales boom at least 40%.
- Kevin Dunleavy
- Overview
- Jobs
Download PDF
COVID-19 has not only changed the global healthcare landscape, but also the old world order for drug developers. In 2021, governments and healthcare systems spent US$36.9 billion on Pfizer’s COVID-19 vaccine Comirnaty (tozinameran), making it the best-selling drug of the year and catapulting Pfizer to the top of the biggest companies list (Fig. 1). A predicted further $33.6 billion of Comirnaty sales this year will help Pfizer remain the biggest pharma company by sales and Comirnaty 2022’s biggest drug. The sheer pace of Comirnaty’s growth since launch means it has become the fastest-selling drug in pharma history. Pfizer’s dominance should be further cemented in 2022 by expected sales of the COVID-19 antiviral Paxlovid (nirmatrelvir and ritonavir), which Pfizer guided could sell $22 billion this year.
While Pfizer has created a gap of over $16 billion between it and nearest rival AbbVie in 2021, sales of Comirnaty and other vaccines are expected to fall sharply in the coming years. Most western countries have now double, if not triple, vaccinated their citizens, and less virulent strains of SARS-CoV-2 are lessening the need for fourth vaccinations for now.
Despite no COVID-19-related products AbbVie rose by one to its second-place spot in 2021, thanks to cash cow Humira (adalimumab), the continued success of the BTK inhibitor Imbruvica (ibrutinib) for blood cancers and sales of psoriasis treatment Skyrizi (risankizumab) rising by 85% in 2021. However, the company will start slipping down the rankings, as biosimilars of Humira enter the market in 2023.
The gains seen by Pfizer and AbbVie have been to the detriment of Novartis and Roche, which dropped two and three places down the rankings since 2020, respectively. Neither company has COVID-19-related products, and the pandemic has resulted in lower-than-expected sales of Ocrevus (ocrelizumab), Roche’s biggest product, due to fears around its immunosuppressive effects. Roche is also still feeling the effects of the biosimilar erosion of some of its biggest products such as Avastin (bevacizumab). Novartis, on the other hand, is struggling with a relatively lacklustre pipeline, which might be remedied through acquisitions using the $20.7 billion it received by selling its 33% stake in Roche last year.
In more normal times, Merck & Co. might have moved up the rankings due to continued strong sales of Keytruda (pembrolizumab), the fourth best-selling drug in 2021. Instead, it remains at number seven. However, the PD1 inhibitor could bank $20 billion of sales this year, as it continues one of pharma’s most successful expansion strategies — a strategy that, barring a shift in the expected need for COVID-19 vaccines, could see Keytruda become the biggest-selling drug in 2023, with revenues of $21.6 billion.
Global Faculty Recruitment of School of Life Sciences, Tsinghua University
The School of Life Sciences at Tsinghua University invites applications for tenure-track or tenured faculty positions at all ranks (Assistant/Ass... Beijing, China Tsinghua University (The School of Life Sciences)
Professor of Biomedical Data Science (Assistant, Associate, and/or Professor Level)
OHSU Knight Cancer Institute CBDS is searching for multiple tenured or tenure-track faculty positions at all ranks in Biomedical Data Science. Portland, Oregon Oregon Health and Science University
Data Scientist (Qualitative)
Houston, Texas (US) Baylor College of Medicine (BCM)
- Lisa Urquhart
Jun 20, 2022 · Here, we rank the top 10 pharma companies by 2021 net income, also known as net earnings or the bottom line. The six largest drugmakers by 2021 revenue—Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis and Merck & Co.—all made the top profits list but in quite a different order.
May 31, 2022 · With Pfizer and BioNTech’s COVID-19 vaccine Comirnaty generating $36.8 billion in sales in 2021—the most for any pharma product in history—Humira couldn't compete for the top spot, even though...
Feb 4, 2022 · Oncology drugs reached $176 billion in sales in 2021, more than double that of the next item on the list, vaccines with $88.6 billion dollars in sales. By 2026, cancer drug sales are expected...
